Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia

References

• Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-20
   PubMed Web of Science ®Google Scholar
• Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk (letter). J Med Genet 2006;43:943-9
   PubMed Web of Science ®Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-12
   PubMed Web of Science ®Google Scholar
• DeMott K, Nherera L, Shaw EJ, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008
   Google Scholar
• Metcalfe S. Technology Assessment Report No. 2. Costs and benefits of simvastatin 40 mg vs fluvastatin 80 mg for patients with familial hyperlipidaemia. Technology Assessment Reports. Wellington, NZ: PHARMAC, 1997
   Google Scholar
• Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-212
   Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z trial. JAMA 2004;292:1307-16
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective randomized, double-blind trial. Lancet 2001;357:577-81
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2006. Available from: http://www.nice.org.uk/Guidance/TA94 [Last accessed 30 October 2009]
   Google Scholar
• Government Actuary’s Department. Interim Life Tables: Government Actuary’s Department, 2006 Available from: http://www.gad.gov.uk/Demography_Data/Life_Tables/Interim_life_tables.asp. [Last accessed 30 October 2009]
   Google Scholar
• Department of Health. NHS Costing Manual 2008/9. Reference Costs 2008. Dept of Health 2008 Available from http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSCostingManual/fs/en. [Last accessed 30 October 2009]
   Google Scholar
• NHS Business Services Authority. Prescription Pricing Division. NHS Electronic Drug Tariff, 2008
   Google Scholar
• Prescott-Clarke P, Primatesta P. Health Survey for England ‘96: The Stationery Office, 1997
   Google Scholar
• Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123-30
   PubMed Web of Science ®Google Scholar
• Packham C, Gray D, Silcocks P, et al. Identifying the risk of death following hospital discharge in patients admitted with a suspected acute myocardial infarction in whom the diagnosis is not confirmed. Eur Heart J 2000;21:213-19
   PubMed Web of Science ®Google Scholar
• Versmissen J, Oosterveer DM, Yazdanapanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J 2008;337: a2423, doi:10.1136/bmj.a2423
   PubMed Web of Science ®Google Scholar
• Neil A, Humphries SE. Statins and familial hypercholesterolaemia. BMJ 2009;338: a3041, doi: 10.1136/bmj.a3041
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423-9
   PubMed Web of Science ®Google Scholar
• Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007;115:2398-2409
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Hypertension: Management of hypertension in adults in primary care. CG34. London: National Institute for Health and Clinical Excellence, 2006. Available from http://guidance.nice.org.uk/CG34.[Last accessed 30 October 2009]
   Google Scholar
• Karnon J, Akehurst R, Brennan A, et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin 2005;21:101-12
   PubMed Web of Science ®Google Scholar
• Mason JM, Freemantle N, Gibson JM, et al. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care 2005;28:40-6
   PubMed Web of Science ®Google Scholar
• Davies A, Hutton J, O’Donnell J, et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006;13:196-202
   Google Scholar
• Yock CA, Boothroyd DB, Owens DK, et al. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med 2003;115:382-9
   PubMed Web of Science ®Google Scholar